

University of Groningen

Prognostic and therapeutic challenges in acute coronary syndromes

Rasoul, Saman

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2007

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Rasoul, S. (2007). *Prognostic and therapeutic challenges in acute coronary syndromes*. [s.n.].

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

List of Publications

Rasoul S, Ottervanger JP, de Boer MJ, Miedema K, Hoorntje JCA, Gosselink ATM, Zijlstra F, Suryapranata H, Dambrink JHE, van 't Hof AWJ. A comparison of dual versus triple antiplatelet therapy in patients with non ST segment elevation acute coronary syndrome. Results of the ELISA-2 trial. *Eur Heart J*. 2006; 27:1401-7.

Rasoul S, Nienhuis MB, Ottervanger JP, Slingerland RJ, MD, de Boer MJ, Dambrink JHE, Ernst NM, Hoorntje JCA, Gosselink ATM, Suryapranata H, Zijlstra F, van 't Hof AWJ. Predictors of Elevated Troponin T on Admission in ST-Segment Elevation Myocardial infarction. *Ann Clin Biochem*. 2006; 43:281-286.

Rasoul S, Svilaas T, Ottervanger T, Timmmer JR, van 't Hof AWJ, Zijlstra F. Glucose-insulin-potassium (GIK) in myocardial infarction: current evidence. *Neth Heart J*. 2006;14:19-23.

van 't Hof AWJ, Rasoul S, van de Wetering H, Ernst N, Suryapranata H, Hoorntje JCA, Dambrink JH E, Gosselink ATM, Zijlstra ATM, Ottervanger JP, de Boer M-J, Shift towards earlier diagnosis and treatment: Feasibility and Benefit of Pre-Hospital Diagnosis, Triage and Therapy by Paramedics only in Patients who are Candidates for Primary Angioplasty for Acute Myocardial Infarction. *Am Heart J*. 2006;151:1255.e1-5.

Rasoul S, Ottervanger JP, Dambrink JHE, de Boer MJ, Hoorntje JCA, Gosselink ATM, Zijlstra F, Suryapranata H, van't Hof AWJ. External validity of ST Elevation Myocardial Infarction Trials: The Zwolle studies. *Catheter and Cardiovasc Interv*. In press.

Rasoul S, Ottervanger JP, Timmer JR, Svilaas T, Henriques JPS, Dambrink JHE, van der Horst ICC, Zijlstra F. One Year Outcomes after Glucose-Insulin-Potassium in ST-Elevation Myocardial Infarction. The Glucose-Insulin-Potassium-Study-II (GIPS-II). *Int J Cardiol*. In press.

Rasoul S, Ottervanger JP, Dambrink JHE, de Boer MJ, Hoorntje JCA, Gosselink ATM, Zijlstra F, Suryapranata H, van 't Hof AWJ. Are Patients with Non-ST Elevation Myocardial Infarction Undertreated? *BMC Cardiovasc Disord*. In press.

List of publications

Rasoul S, Ottervanger JP, Bilo HJG, Timmer JR, van 't Hof AWJ, Dambrink JHE, Dikkeschei BLD, Hoorntje JCA, de Boer MJ, Zijlstra F. Glucose dysregulation in non-diabetic patients with ST-segment elevation myocardial infarction predicts mainly short- term prognosis. *Neth J Med*. In press.

Rasoul S, Ottervanger JP, de Boer MJ, Dambrink JHE, Suryapranata H, Hoorntje JCA, Gosselink ATM, van 't Hof AWJ, on behalf of the ELISA study group. Routine upstream versus selective down stream use of Tirofiban in non-ST elevation myocardial infarction patients scheduled for early invasive therapy; a randomized comparison. *J Thromb Thrombolysis*. In press.

Rasoul S, Carretero OA, Peng H, Cavasin MA, Zhuo J, Rhaleb N-E. Angiotensin converting enzyme inhibition and acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) lower cardiac inflammation and fibrosis in hypertension. *J Hypertension*. 2004;22:593-603.

Pokharel S, Rasoul S, Roks AJM, van Luyn MJA, Deelman LE, Smits JF, Carretero OA, van Gils WH, Pinto YM. N-Acetyl-Ser-Asp-Lys-Pro (AcSDKP) Inhibits the Phosphorylation of SMAD in Cardiac Fibroblasts: A Novel Pathway to Explain ACE Inhibitor Effects. *Hypertension*. 2002; 40:155-61

Rasoul S, Rhaleb NE, Peng P, Pinto YM, Carretero OA. N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) inhibits macrophage activation and infiltration. *Circulation* 2001;104,17 P335 [abstract].

van 't Hof AW, Rasoul S, Ottervanger JP, Dambrink JHE. Facilitation of primary PCI with ReoPro. *Eur Heart J*. 2005; 26:1563-4 [letter].

Rasoul S, de Boer MJ, Suryapranata H, Hoorntje JCA, Gosselink ATM, Zijlstra F, Ottervanger JP, Dambrink JHD, van 't Hof AWJ. Circumflex Artery Related Acute Myocardial Infarction: Limited ECG Abnormalities but Poor Outcome. Submitted.

Rasoul S, Ottervanger JP, de Boer MJ, Dambrink JHE, Hoorntje JCA, Gosselink ATM, Zijlstra F, Suryapranata H, van 't Hof AWJ. Primary PCI for ST-Elevation Myocardial Infarction: from Clinical Trial to Clinical Practice. Submitted.